Carisma Therapeutics, Inc.
CARM · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.09 | 0.01 | -0.01 | -0.05 |
| FCF Yield | -36.08% | -77.74% | -48.11% | -31.93% |
| EV / EBITDA | -2.78 | -0.87 | -0.12 | -1.39 |
| Quality | ||||
| ROIC | 200.21% | -130.66% | -99.88% | -38.70% |
| Gross Margin | 0.00% | 100.00% | 81.69% | 100.00% |
| Cash Conversion Ratio | 0.04 | 0.60 | 1.09 | 0.47 |
| Growth | ||||
| Revenue 3-Year CAGR | -19.89% | -6.36% | 17.66% | 25.92% |
| Free Cash Flow Growth | 41.35% | -20.53% | 35.85% | 19.76% |
| Safety | ||||
| Net Debt / EBITDA | 0.05 | 0.62 | 1.00 | 1.90 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,202.61 | 29.18 | -209.39 | -211.02 |